An observational study Background: Gender differences vary across geographical settings and are poorly reported in the literature. The aim of this study published in Sexual Health [1] was to evaluate demographics and clinical characteristics of participants from the Australian HIV Observational Database (AHOD), and to explore any differences between females and males in the rate of new clinical outcomes, as well as initial immunological and virological response to antiretroviral therapy.
Patients under active follow up 1 (n=2002) (n=2035) (n=2047) (n=2023) (n=2132) (n=2285) (n=2372) (n=2547) (n=2541) (n=2537) (n=2408)
Never treatment
73 (4) 72 (4) 71 (3) 69 (3) 57 (3) 69 (3) 71 (3) 86 (3) 72 (3) 57 (2) 43 (2 (14) 237 (12) 240 (12) 189 (9) 170 (8) 147 (6) 139 (6) 86 (3) 62 (2) 47 (2) 33 (1 1. First ART defined as a combination of 3 or more antiretroviral agents and a duration of ART>14 days. Includes retrospective and prospective data. ATRAS sub study participants excluded from analysis. 2. CD4 cell count selected from the observation closest to ART start date within a timeframe window of 12 months prior to ART start date and 7 days post ART start date. 3. A patient was excluded from the analysis if an undetectable viral load was recorded prior to initiating ART or was missing a viral load measurement prior to initiating ART. (17) 312 (13) 258 (11) 224 (9) 206 (8) 169 (7) 140 (5) 109 (4) 90 (4) 76 (3) Didanosine 281 (13) 205 (9) 135 (6) 94 (4) 63 (3) 53 (2) 34 (1) 29 (1) 21 (1) 18 (1) 13 (1) Emtricitabine 39 (2) 100 (4) 86 (4) 129 (5) 164 (7) 206 (8) 228 (9) 231 (9) (6) 88 (4) 69 (3) 51 (2) 39 (2) 24 (1) 22 (1) 14 (1) 11 (0) 150 (7) 123 (5) 86 (4) 69 (3) 56 (2) 44 (2) 40 (2) 27 (1) 21 (1) 19 (1) (1) 53 (2) 85 (4) 104 (4) 111 (4) 118 (4) 121 (5) 121 (5) 122 (5) (1) 36 (1) 43 (2) 41 (2) Entry Inhibitor Enfurvitide 63 (3) 69 (3) 62 (3) 45 (2) 28 (1) 17 (1) (1) 22 (1) 29 (1) 33 (1) 42 (2) 49 (2) 50 (2) 46 (2) 1. All treatment records of ≥2 weeks of treatment in any calendar year were included in this analysis. The denominator includes all patients that could have been on antiretroviral therapy (i.e. HIV positive) in any calendar year. The proportion of patients on each drug in any calendar year does not add up to 100% across all ART drug groups in each calendar year as patients on more than one ARV during a calendar year period will be counted in all of the relevant ART groups. Includes retrospective and prospective data. 
Protease Inhibitor
Amprenavir 446 (20) 30 (1) 28 (1) 27 (1) 27 (1) 24 (1) 20 (1) 18 (1) 15 (1) 13 (1) (1) 42 (2) 74 (3) 120 (5) 165 (7) 199 (8) 231 (9) 269 (10) 279 (11) 301 (12) 299 (12) Fosamprenavir 31 (1) 36 (2) 32 (1) 30 (1) 24 (1) 17 (1) 15 (1) 13 (0) 11 (0) 10 (0) 7 (0) Indinavir 72 (3) 48 (2) 33 (1) 21 (1) 11 (0) 
446 (20) 413 (18) 389 (17) 363 (15) 340 (14) 328 (13) 288 (11) 249 (9) 201 (8) 164 (6) 115 (5) Nelfinavir 72 (3) 47 (2) 35 (2) 9 (0) (4) 70 (3) 44 (2) 35 (1) 32 (1) 27 (1) 23 (1) 18 (1) 13 (1 
1. All treatment records of ≥2 weeks of treatment in any calendar year were included in this analysis. The denominator includes all patients that could have been on antiretroviral treatment (i.e. HIV positive) in any calendar year. The proportion of patients on each drug in any calendar year does not add up to 100% across all ARV drug groups in each calendar year as patients on more than one ART during a calendar year period will be counted in all of the relevant ART groups. Includes retrospective and prospective data. For the time period 2009 -2013, to estimate the number of patients receiving ART, we combined data on the proportion of patients receiving certain mutually exclusive ARVs in AHOD with data from the s100 program on the total number of people receiving the same ARVs. For example, lamivudine and emtricitabine are a common component of combination ART regimens in Australia, but should not be prescribed in combination. We calculated the proportion of all treated patients in AHOD who received lamivudine or emtricitabine as part of an ART regimen by year and state. We also estimated the total number of patients dispensed lamivudine or emtricitabine for HIV infection each year through the s100 program by calculating the average number of patients prescribed each drug from the corresponding four financial year quarters. An estimate of the total number of people receiving any ART was then obtained by dividing the total number of patients receiving lamivudine or emtricitabine through the s100 program by the proportion of treated patients in AHOD receiving the same ARV drugs.
Note: Prior to 2009, the HSD Report provided prescribed patient numbers by each antiretroviral agent. However after noting some inconsistencies with their methodology, they have since ceased providing these numbers. For years 2009-2010, instead we (The Kirby Institute) evaluated patient numbers by using a combination of total packs dispensed and an average "packs-per-patient" adjustment ratio. The packs-per-patient adjustment figure was calculated from 2008 data, where total packs dispensed and patient numbers were available. However, due to the relatively recent diversification of pack sizes, newer dosing schedules and the introduction of antiretroviral agents that were absent in 2008, we are uncertain as to how our packs-per-patient adjustment ratio has changed over time. Therefore we caution our estimates for 2011-2013 data for Table 11 .
From 2014 onwards, we report the number of people receiving ART based on a 10% sample of the Pharmaceutical Benefits Scheme (PBS) data, including s100 drugs. Data on dispensed prescriptions for a PBS 10% sample is updated every quarter and supplied to a number of approved users or clients including Prospection which provides a dashboard interface (PharmDash) for querying the PBS 10% sample [1, 2] . The 10% sample of the PBS is a randomised patient level, de-identified PBS script claims data set from 2006-present. Currently the data set has 170 million script claims and 3 million patients. It includes all PBS listed drugs with HIV indications. The presented figures are annual totals of unique patients in December each year. This represents total number of patients obtaining at least one prescription for the indicated drug anytime during a year. This methodology is preferable due to increased accuracy of the source data and the removal of assumptions and extrapolations previously required. This may also explain the considerable increase in estimated number of patients receiving ART from 2013 to 2014.
[1] http://www.pbs.gov.au/info/industry/useful-resources/sources/, 22 September 2015.
[2] http://www.prospection.com.au/, 22 September 2015.
